Latest news with #NovoCure
Yahoo
5 days ago
- Business
- Yahoo
NovoCure Second Quarter 2025 Earnings: Beats Expectations
NovoCure (NASDAQ:NVCR) Second Quarter 2025 Results Key Financial Results Revenue: US$158.8m (up 5.6% from 2Q 2024). Net loss: US$40.1m (loss widened by 20% from 2Q 2024). US$0.36 loss per share (further deteriorated from US$0.31 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period NovoCure Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 7.4%. Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are down 25% from a week ago. Risk Analysis Before we wrap up, we've discovered 1 warning sign for NovoCure that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Globe and Mail
21-07-2025
- Business
- Globe and Mail
Glioblastoma Pipeline Appears Promising With 200+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
DelveInsight's, ' Glioblastoma Pipeline Insight, 2025 ' report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Glioblastoma Pipeline Report to explore emerging therapies, key Glioblastoma Companies, and future Glioblastoma treatment landscapes @ Glioblastoma Pipeline Outlook Report Key Takeaways from the Glioblastoma Pipeline Report In July 2025, NovoCure GmbH announced a study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS). In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM). DelveInsight's Glioblastoma pipeline report depicts a robust space with 200+ active players working to develop 220+ pipeline therapies for Glioblastoma treatment. The leading Glioblastoma Companies such as Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others. Promising Glioblastoma Pipeline Therapies such as Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others. Stay informed about the cutting-edge advancements in Glioblastoma treatments. Download for updates and be a part of the revolution in Oncology Care @ Glioblastoma Clinical Trials Assessment Glioblastoma Emerging Drugs Profile BMX-001: BioMimetix BMX-001 is a metalloporphyrin, a novel class of redox-active, small molecule. The active center is designed to mimic the center of superoxide dismutase. The primary mechanism of action is modulation of cellular signaling pathways. BMX-001 inhibits both NFkB and HIF-1a. By inhibiting these pro-survival and pro-angiogenic transcription factors, BMX-001 augments tumor killing by radiation therapy and inhibits tumor regrowth. The inhibition of NFkB blocks major components of the inflammatory cascade which simultaneously results in protection of normal tissue from radiation induced injury. BMX-001 is also being developed in head and neck cancer, anal cancer, and rectal cancer. Currently, the drug is in the Phase III stage of its development for the treatment of glioblastoma. Enzastaurin: Denovo BioPharma DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world's first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM). MDNA55: Medicenna Therapeutics, Inc. MDNA55 is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. The drug is currently under Phase II of development. MN-166: MediciNova MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses the pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6 and might up-regulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. While considered a New Molecular Entity, or NME, in the United States and Europe, it involves the redirection of an approved drug, ibudilast, which was first approved in Japan more than 20 years ago. Ibudilast has been prescribed to over 3.2 million patients and has a good post-marketing safety profile. Currently, the drug is in Phase II trial for the treatment of Glioblastoma. TNG456: Tango Therapeutics, Inc. TNG456 is an experimental targeted therapy developed to address the aggressive nature of glioblastoma, one of the most treatment-resistant brain tumors. Designed to inhibit key molecular pathways involved in tumor proliferation and immune evasion, TNG456 aims to enhance both direct tumor suppression and immune system activation. Preclinical data suggest potential synergy when used alongside standard-of-care therapies like radiotherapy or temozolomide. Its mechanism may involve disrupting tumor metabolism or modulating the tumor microenvironment. TNG456 represents a promising candidate in the evolving landscape of glioblastoma therapeutics, currently under investigation for efficacy and safety. The drug is currently in Phase I/II stage of its development for the treatment of glioblastoma. The Glioblastoma Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment. Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market. Learn more about Glioblastoma Drugs opportunities in our groundbreaking Glioblastoma research and development projects @ Glioblastoma Unmet Needs Glioblastoma Companies Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others. Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Glioblastoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Discover the latest advancements in Glioblastoma treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Glioblastoma Market Drivers and Barriers, and Future Perspectives Scope of the Glioblastoma Pipeline Report Coverage- Global Glioblastoma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others. Glioblastoma Pipeline Therapies- Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others. Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Glioblastoma Pipeline on our website @ Glioblastoma Emerging Drugs and Companies Table of Contents Introduction Executive Summary Glioblastoma: Overview Pipeline Therapeutics Therapeutic Assessment Glioblastoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Enzastaurin: Denovo BioPharma Mid Stage Products (Phase II) MDNA55: Medicenna Therapeutics, Inc. Early Stage Products (Phase I/II) TNG456: Tango Therapeutics, Inc. Preclinical and Discovery Stage Products RGN6024: Reglagene, Inc. Inactive Products Glioblastoma Key Companies Glioblastoma Key Products Glioblastoma- Unmet Needs Glioblastoma- Market Drivers and Barriers Glioblastoma- Future Perspectives and Conclusion Glioblastoma Analyst Views Glioblastoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
28-05-2025
- Business
- Yahoo
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
NovoCure's stock is down significantly this year, partly due to persistent net losses. However, the company is making significant clinical and regulatory progress. Although there are some risks, the stock could surge due to significant catalysts. 10 stocks we like better than NovoCure › It's been a challenging year for NovoCure (NASDAQ: NVCR), an oncology-focused biotech. The stock is down by 35% since early January. Though marketwide issues probably didn't help, NovoCure mostly has itself to blame for its year-to-date performance. Its shares declined after a disappointing fourth-quarter update. Still, the stock could have significant upside potential. NovoCure's average price target on Wall Street is $32.57, according to Yahoo! Finance. That implies it could jump by almost 70% from its current levels. Should investors be as bullish as the Street on NovoCure? NovoCure develops and markets wearable devices that emit electrical fields, known as tumor-treating fields (TTFields), which inhibit the growth of cancer cells. These devices don't necessarily replace traditional therapies; they are often used concurrently with them (although in some cases, they can be stand-alone treatments). This innovative approach to treating one of the leading causes of death worldwide has found some success. NovoCure markets two devices: Optune Gio, cleared to treat an aggressive type of brain cancer called glioblastoma, and Optune Lua, approved to target both metastatic non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, a rare, aggressive lung cancer. Greater adoption of these devices in markets where they're available is helping improve NovoCure's financial results. In the first quarter, the company's revenue increased by 12% year over year to $155 million. It had 4,268 active patients on therapy as of the end of the period, an 11% increase compared to the year-ago period. However, NovoCure remains unprofitable; its net loss per share in the first quarter was $0.31. True, that was better than the $0.36 reported in the year-ago period. But given the uncertain environment and ongoing market volatility, investors may have a deep bias for well-established, profitable stocks at the moment. So NovoCure's shares could remain somewhat turbulent in the short run. However, recent developments could help the company turn things around and match the Street's estimates. NovoCure has achieved several clinical and regulatory milestones in the past six months. In April, it received clearance from the relevant European authority for Optune Lua for the treatment of metastatic NSCLC. NovoCure estimates that more than 400,000 patients are diagnosed with NSCLC every year on the continent. Though its device will only target a small portion of this total, the regulatory nod significantly expands its addressable market. Optune Lua has been approved in the U.S. for NSCLC only since October. In the U.S., approximately 30,000 patients become eligible for the device out of 193,000 annual NSCLC diagnoses. NovoCure still has a massive white space in this niche -- even getting to 5,000 patients in NSCLC alone would be a gigantic win for the company. Meanwhile, in December, it announced positive results from a phase 3 clinical trial for its TTFields for unresectable, locally advanced pancreatic adenocarcinoma. This was the first time any treatment showed a statistically significant benefit in overall survival for patients with this type of pancreatic cancer, which is mostly out of reach by current standards of care. It has a five-year survival rate of just 13%, while its death rates are increasing, even as they decrease for most other types of cancer. NovoCure estimates 67,000 annual diagnoses in the U.S., so there is a vast unmet need. The company appears likely to secure another key approval here and go on to make progress in this field. Yet the stock is still down massively for the year, even though it jumped following recent developments, including the NSCLC approval in Europe. What gives? NovoCure's consistent net losses remain a concern. However, if you're willing to look past those and the somewhat elevated risk they add to the stock, NovoCure could be an excellent pickup at current levels. Pending approval in pancreatic cancer and solid progress in NSCLC, revenue could grow substantially and allow the healthcare specialist to turn a profit. Wall Street analysts might be onto something here. But if you follow their lead, it's essential to start with a small position in the stock and then add more only once (or if) it continues to show good progress. Before you buy stock in NovoCure, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and NovoCure wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure. The Motley Fool has a disclosure policy. 1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street was originally published by The Motley Fool
Yahoo
25-04-2025
- Business
- Yahoo
Why NovoCure Stock Skyrocketed This Week
Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%. Why? The medical technology company reported solid first-quarter results. The company also provided several key updates that investors reacted positively to. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » A key highlight from NovoCure's earnings call was the announcement of European CE Mark approval for OptuneLua in the treatment of metastatic non-small cell lung cancer (NSCLC). The CE Mark allows the company to market the device in Europe. OptuneLua, a medical device that emits an electric field disrupting cancer cells, uses NovoCure's core technology. The launch in Europe is an important milestone in the company's international expansion strategy and will help the company drive revenue growth. Investors also received promising news regarding NovoCure's Phase 3 clinical trial for patients with a specific type of pancreatic cancer that is particularly hard to treat. The trial data showed a "meaningful survival benefit" and is the first to do so for this particular cancer. The results mean the company could open another major market for NovoCure's tumor treating technology. NovoCure reported $155 million in net revenue for Q1 2025, representing a 12% increase year over year. This growth was driven by expansion of the company's active patient base, especially in France, Japan, Germany, and the United States. As the company grows, its margins were slightly reduced, from 76% to 75% year over year. The reduction was explained, however, by a lag in reimbursement for some of its treatments. The company is still operating at a loss, however, losing $34 million this quarter. That's not unusual for a company in NovoCure's position, however. As the company launches in Europe and continues to prove its technology is useful in more indications, its revenue could grow considerably. I think the stock is headed in the right direction and is a solid pick for those with an elevated risk tolerance. Before you buy stock in NovoCure, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and NovoCure wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $591,533!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $652,319!* Now, it's worth noting Stock Advisor's total average return is 859% — a market-crushing outperformance compared to 158% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure. The Motley Fool has a disclosure policy. Why NovoCure Stock Skyrocketed This Week was originally published by The Motley Fool
Yahoo
24-04-2025
- Business
- Yahoo
Why NovoCure Stock Leaped 4% Higher Today
Thursday morning NovoCure (NASDAQ: NVCR) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index. For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. That was a nearly 12% improvement over the same period of 2024. Compounding that, the biotech managed to narrow its generally accepted accounting principles (GAAP) net loss by roughly the same percentage; it landed at $34.4 million ($0.31 per share) against the Q1 2024 shortfall of $38.8 million. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » As a group, analysts tracking NovoCure's fortunes weren't expecting the company to do so well. Their collective estimate for net revenue was under $148 million; for headline net loss it was $0.49 per share. Although NovoCure is one of a big clutch of biotechs developing cancer therapies, it's unique in the segment. Its money technology is tumor treating fields (TTFs), which as the name suggests are electrical fields produced by a small device powered by a battery. These fields hold the promise of treating various cancers without the often heavy side effects of other therapies. NovoCure is also making a concentrated effort to branch out, an effort that's clearly appreciated by the market. It quoted CEO Ashley Cordova as saying that "our footprint is expanding across new indications, new centers, and new physician specialties." I'm not sure TTFs will become the go-to oncology treatment in the market, but the technology sure is intriguing and well worth watching. NovoCure stock is worth considering on that basis, in my view. Before you buy stock in NovoCure, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and NovoCure wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $566,035!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $629,519!* Now, it's worth noting Stock Advisor's total average return is 829% — a market-crushing outperformance compared to 155% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure. The Motley Fool has a disclosure policy. Why NovoCure Stock Leaped 4% Higher Today was originally published by The Motley Fool Sign in to access your portfolio
